354 related articles for article (PubMed ID: 32293527)
1. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.
Hill LF; Turner MA; Lutsar I; Heath PT; Hardy P; Linsell L; Jacqz-Aigrain E; Roilides E; Sharland M;
Trials; 2020 Apr; 21(1):329. PubMed ID: 32293527
[TBL] [Abstract][Full Text] [Related]
2. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M;
Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669
[TBL] [Abstract][Full Text] [Related]
3. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.
Lutsar I; Trafojer UM; Heath PT; Metsvaht T; Standing J; Esposito S; de Cabre VM; Oeser C; Aboulker JP;
Trials; 2011 Sep; 12():215. PubMed ID: 21958494
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.
Jacqz-Aigrain E; Leroux S; Thomson AH; Allegaert K; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Nakamura H; van den Anker JN; Sharland M; Zhao W
J Antimicrob Chemother; 2019 Aug; 74(8):2128-2138. PubMed ID: 31049551
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy of a 7-day versus a 14-day course of intravenous antibiotics in the treatment of uncomplicated neonatal bacterial sepsis: study protocol of a randomized controlled non-inferiority trial.
Dutta S; Nangia S; Jajoo M; Gathwala G; Nesargi S; Sundaram M; Kumar P; Saili A; Kumar D; Dalal P; Suman Rao PN; Shanmugam R; Ray P; Randhawa VS; Saigal K; Sharma M; Nagaraj S; Radhakrishnan D
Trials; 2021 Nov; 22(1):859. PubMed ID: 34844643
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices.
Rubin LG; Sánchez PJ; Siegel J; Levine G; Saiman L; Jarvis WR;
Pediatrics; 2002 Oct; 110(4):e42. PubMed ID: 12359815
[TBL] [Abstract][Full Text] [Related]
7. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
8. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.
Lutsar I; Chazallon C; Trafojer U; de Cabre VM; Auriti C; Bertaina C; Calo Carducci FI; Canpolat FE; Esposito S; Fournier I; Hallik M; Heath PT; Ilmoja ML; Iosifidis E; Kuznetsova J; Meyer L; Metsvaht T; Mitsiakos G; Pana ZD; Mosca F; Pugni L; Roilides E; Rossi P; Sarafidis K; Sanchez L; Sharland M; Usonis V; Warris A; Aboulker JP; Giaquinto C;
PLoS One; 2020; 15(3):e0229380. PubMed ID: 32130261
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin for prophylaxis against sepsis in preterm neonates.
Craft AP; Finer NN; Barrington KJ
Cochrane Database Syst Rev; 2000; 2000(2):CD001971. PubMed ID: 10796456
[TBL] [Abstract][Full Text] [Related]
10. Empirical antimicrobial therapy for late-onset sepsis in a neonatal unit with high prevalence of coagulase-negative Staphylococcus.
Romanelli RM; Anchieta LM; Bueno E Silva AC; de Jesus LA; Rosado V; Clemente WT
J Pediatr (Rio J); 2016; 92(5):472-8. PubMed ID: 27112033
[TBL] [Abstract][Full Text] [Related]
11. How to use vancomycin optimally in neonates: remaining questions.
Jacqz-Aigrain E; Leroux S; Zhao W; van den Anker JN; Sharland M
Expert Rev Clin Pharmacol; 2015; 8(5):635-48. PubMed ID: 26289222
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of cephalothin versus vancomycin therapy in the treatment of coagulase-negative staphylococcal septicemia in neonates: relation to methicillin resistance and mec A gene carriage of blood isolates.
Krediet TG; Jones ME; Gerards LJ; Fleer A
Pediatrics; 1999 Mar; 103(3):E29. PubMed ID: 10049985
[TBL] [Abstract][Full Text] [Related]
13. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.
Rao SC; Ahmed M; Hagan R
Cochrane Database Syst Rev; 2006 Jan; (1):CD005091. PubMed ID: 16437518
[TBL] [Abstract][Full Text] [Related]
14. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
James JK; Palmer SM; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
[TBL] [Abstract][Full Text] [Related]
15. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.
Ramos-Martín V; Johnson A; Livermore J; McEntee L; Goodwin J; Whalley S; Docobo-Pérez F; Felton TW; Zhao W; Jacqz-Aigrain E; Sharland M; Turner MA; Hope WW
J Antimicrob Chemother; 2016 Apr; 71(4):992-1002. PubMed ID: 26755499
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial.
Gwee A; Cranswick N; Donath SM; Hunt R; Curtis N
BMJ Open; 2018 Nov; 8(11):e022603. PubMed ID: 30391914
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Huang DB; File TM; Torres A; Shorr AF; Wilcox MH; Hadvary P; Dryden M; Corey GR
Clin Ther; 2017 Aug; 39(8):1706-1718. PubMed ID: 28756068
[TBL] [Abstract][Full Text] [Related]
20. Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: a retrospective cohort study.
Lawrence SL; Roth V; Slinger R; Toye B; Gaboury I; Lemyre B
BMC Pediatr; 2005 Dec; 5():49. PubMed ID: 16375769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
